206 related articles for article (PubMed ID: 34088831)
21. Identification of MYCN non-amplified neuroblastoma subgroups points towards molecular signatures for precision prognosis and therapy stratification.
Hu X; Zhou Y; Hill C; Chen K; Cheng C; Liu X; Duan P; Gu Y; Wu Y; Ewing RM; Li Z; Wu Z; Wang Y
Br J Cancer; 2024 May; 130(11):1841-1854. PubMed ID: 38553589
[TBL] [Abstract][Full Text] [Related]
22. Targeted Degradation of XIAP is Sufficient and Specific to Induce Apoptosis in MYCN-overexpressing High-risk Neuroblastoma.
Choo Z; Koh X; Wong MRE; Ashokan RM; Ali Ahamed NSB; Kang C; Kuick CH; Chang KTE; Larisch S; Loh AHP; Chen ZX
Cancer Res Commun; 2023 Nov; 3(11):2386-2399. PubMed ID: 37874199
[TBL] [Abstract][Full Text] [Related]
23. 4-Hydroxychalcone Induces Cell Death via Oxidative Stress in
Alshangiti AM; Tuboly E; Hegarty SV; McCarthy CM; Sullivan AM; O'Keeffe GW
Oxid Med Cell Longev; 2019; 2019():1670759. PubMed ID: 31885773
[TBL] [Abstract][Full Text] [Related]
24. Venetoclax plus cyclophosphamide and topotecan in heavily pre-treated relapsed metastatic neuroblastoma: a single center case series.
De Ioris MA; Fabozzi F; Del Bufalo F; Del Baldo G; Villani MF; Cefalo MG; Garganese MC; Stracuzzi A; Tangari F; Greco AM; Giovannoni I; Carta R; D'Andrea ML; Mastronuzzi A; Locatelli F
Sci Rep; 2023 Nov; 13(1):19295. PubMed ID: 37935707
[TBL] [Abstract][Full Text] [Related]
25. Histone lysine demethylase 4 family proteins maintain the transcriptional program and adrenergic cellular state of MYCN-amplified neuroblastoma.
Abu-Zaid A; Fang J; Jin H; Singh S; Pichavaram P; Wu Q; Tillman H; Janke L; Rosikiewicz W; Xu B; Van De Velde LA; Guo Y; Li Y; Shendy NAM; Delahunty IM; Rankovic Z; Chen T; Chen X; Freeman KW; Hatley ME; Durbin AD; Murray PJ; Murphy AJ; Thomas PG; Davidoff AM; Yang J
Cell Rep Med; 2024 Mar; 5(3):101468. PubMed ID: 38508144
[TBL] [Abstract][Full Text] [Related]
26. MCPIP1 ribonuclease can bind and cleave
Nowak I; Boratyn E; Student S; Bernhart SF; Fallmann J; Durbas M; Stadler PF; Rokita H
RNA Biol; 2021 Jan; 18(1):144-156. PubMed ID: 32757706
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of clinically translatable MR imaging biomarkers of therapeutic response in the TH-MYCN transgenic mouse model of neuroblastoma.
Jamin Y; Tucker ER; Poon E; Popov S; Vaughan L; Boult JK; Webber H; Hallsworth A; Baker LC; Jones C; Koh DM; Pearson AD; Chesler L; Robinson SP
Radiology; 2013 Jan; 266(1):130-40. PubMed ID: 23169794
[TBL] [Abstract][Full Text] [Related]
28. MYCN amplification and ATRX mutations are incompatible in neuroblastoma.
Zeineldin M; Federico S; Chen X; Fan Y; Xu B; Stewart E; Zhou X; Jeon J; Griffiths L; Nguyen R; Norrie J; Easton J; Mulder H; Yergeau D; Liu Y; Wu J; Van Ryn C; Naranjo A; Hogarty MD; Kamiński MM; Valentine M; Pruett-Miller SM; Pappo A; Zhang J; Clay MR; Bahrami A; Vogel P; Lee S; Shelat A; Sarthy JF; Meers MP; George RE; Mardis ER; Wilson RK; Henikoff S; Downing JR; Dyer MA
Nat Commun; 2020 Feb; 11(1):913. PubMed ID: 32060267
[TBL] [Abstract][Full Text] [Related]
29. HAND2 Assists MYCN Enhancer Invasion to Regulate a Noradrenergic Neuroblastoma Phenotype.
Xu M; Sun M; Zhang X; Nguyen R; Lei H; Shern JF; Thiele CJ; Liu Z
Cancer Res; 2023 Mar; 83(5):686-699. PubMed ID: 36598365
[TBL] [Abstract][Full Text] [Related]
30. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity.
Yang Y; Wang S; Cai J; Liang J; Zhang Y; Xie Y; Luo F; Tang J; Gao Y; Shen S; Feng H; Li Y
Cell Oncol (Dordr); 2023 Feb; 46(1):133-143. PubMed ID: 36520365
[TBL] [Abstract][Full Text] [Related]
31. MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner.
Castell A; Yan Q; Fawkner K; Bazzar W; Zhang F; Wickström M; Alzrigat M; Franco M; Krona C; Cameron DP; Dyberg C; Olsen TK; Verschut V; Schmidt L; Lim SY; Mahmoud L; Hydbring P; Lehmann S; Baranello L; Nelander S; Johnsen JI; Larsson LG
Cancer Res Commun; 2022 Mar; 2(3):182-201. PubMed ID: 36874405
[TBL] [Abstract][Full Text] [Related]
32. Combined inhibition of Aurora-A and ATR kinase results in regression of
Roeschert I; Poon E; Henssen AG; Garcia HD; Gatti M; Giansanti C; Jamin Y; Ade CP; Gallant P; Schülein-Völk C; Beli P; Richards M; Rosenfeldt M; Altmeyer M; Anderson J; Eggert A; Dobbelstein M; Bayliss R; Chesler L; Büchel G; Eilers M
Nat Cancer; 2021 Mar; 2(3):312-326. PubMed ID: 33768209
[TBL] [Abstract][Full Text] [Related]
33. Statin-induced Mitochondrial Priming Sensitizes Multiple Myeloma Cells to BCL2 and MCL-1 Inhibitors.
Juarez D; Buono R; Matulis SM; Gupta VA; Duong M; Yudiono J; Paul M; Mallya S; Diep G; Hsin P; Lu A; Suh SM; Dong VM; Roberts AW; Leverson JD; Jalaluddin M; Liu Z; Bueno OF; Boise LH; Fruman DA
Cancer Res Commun; 2023 Dec; 3(12):2497-2509. PubMed ID: 37956312
[TBL] [Abstract][Full Text] [Related]
34. LRP8-mediated selenocysteine uptake is a targetable vulnerability in MYCN-amplified neuroblastoma.
Alborzinia H; Chen Z; Yildiz U; Freitas FP; Vogel FCE; Varga JP; Batani J; Bartenhagen C; Schmitz W; Büchel G; Michalke B; Zheng J; Meierjohann S; Girardi E; Espinet E; Flórez AF; Dos Santos AF; Aroua N; Cheytan T; Haenlin J; Schlicker L; Xavier da Silva TN; Przybylla A; Zeisberger P; Superti-Furga G; Eilers M; Conrad M; Fabiano M; Schweizer U; Fischer M; Schulze A; Trumpp A; Friedmann Angeli JP
EMBO Mol Med; 2023 Aug; 15(8):e18014. PubMed ID: 37435859
[TBL] [Abstract][Full Text] [Related]
35. Targeting mitochondria by α-tocopheryl succinate kills neuroblastoma cells irrespective of MycN oncogene expression.
Kruspig B; Nilchian A; Bejarano I; Orrenius S; Zhivotovsky B; Gogvadze V
Cell Mol Life Sci; 2012 Jun; 69(12):2091-9. PubMed ID: 22286068
[TBL] [Abstract][Full Text] [Related]
36. Impaired Antitumor Immune Response in
Kacher J; Manches O; Aspord C; Sartelet H; Chaperot L
Cancer Res Commun; 2022 Jul; 2(7):577-589. PubMed ID: 36923280
[TBL] [Abstract][Full Text] [Related]
37. In vivo cisplatin-resistant neuroblastoma metastatic model reveals tumour necrosis factor receptor superfamily member 4 (TNFRSF4) as an independent prognostic factor of survival in neuroblastoma.
Murphy C; Devis-Jauregui L; Struck R; Boloix A; Gallagher C; Gavin C; Cottone F; Fernandez AS; Madden S; Roma J; Segura MF; Piskareva O
PLoS One; 2024; 19(5):e0303643. PubMed ID: 38809883
[TBL] [Abstract][Full Text] [Related]
38. Vitamin K3 derivative induces apoptotic cell death in neuroblastoma via downregulation of MYCN expression.
Yoda H; Nakayama T; Miura M; Toriyama M; Motohashi S; Suzuki T
Biochem Biophys Rep; 2019 Dec; 20():100701. PubMed ID: 31844686
[TBL] [Abstract][Full Text] [Related]
39. ALK expression, prognostic significance, and its association with MYCN expression in MYCN non-amplified neuroblastoma.
Somasundaram DB; Aravindan S; Gupta N; Yu Z; Baker A; Aravindan N
World J Pediatr; 2022 Apr; 18(4):285-293. PubMed ID: 35132576
[No Abstract] [Full Text] [Related]
40. Role of MRI radiomics for the prediction of MYCN amplification in neuroblastomas.
Ghosh A; Yekeler E; Teixeira SR; Dalal D; States L
Eur Radiol; 2023 Oct; 33(10):6726-6735. PubMed ID: 37178203
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
